ContentsSynopsisCodesLook ForDiagnostic PearlsDifferential Diagnosis & PitfallsBest TestsManagement PearlsTherapyReferences
Metachromatic leukodystrophy
Print
Other Resources UpToDate PubMed

Metachromatic leukodystrophy

Print Images (1)
Contributors: Bo Hoon Lee MD, Jamie Adams MD, Richard L. Barbano MD, PhD
Other Resources UpToDate PubMed

Synopsis

Metachromatic leukodystrophy (MLD) is an autosomal recessive disorder caused by mutations in the ARSA gene, which encodes arylsulfatase A enzyme. Arylsulfatase A deficiency leads to impaired breakdown of sulfatides. Sulfatide accumulation in the central nervous system (CNS) leads to myelin breakdown. Sulfatides can also accumulate in the peripheral nervous system, kidneys, and gallbladder.

MLD is characterized by 3 clinical subtypes with variable age of onset and progression:
  • Late-infantile MLD is the most common and has onset before 30 months of age; it typically presents with progressive hypotonia, weakness, and dysarthria and regression of cognitive, language, and motor skills. Most children die within 5 years after onset of symptoms.
  • Juvenile MLD has onset between 30 months and 16 years of age. Initial symptoms can involve worsening school performance, personality changes, and behavioral issues. Progression of neurologic symptoms is variable. The majority of patients die before 20 years of age.
  • Adult MLD has onset after 16 years of age and has a highly variable presentation. Initial symptoms often involve declining job performance or psychiatric symptoms, often leading to initial diagnosis of mood disorders or psychosis. Neurologic symptoms include weakness, peripheral neuropathy, loss of coordination, and spasticity.
For more information, see OMIM.

Codes

ICD10CM:
E75.25 – Metachromatic leukodystrophy

SNOMEDCT:
396338004 – Metachromatic leukodystrophy

Look For

Subscription Required

Diagnostic Pearls

Subscription Required

Differential Diagnosis & Pitfalls

Arylsulfatase A activity may be low in many other disorders (pseudodeficiency). Urinary sulfatides should be measured as the next confirmatory step.

Best Tests

Subscription Required

Management Pearls

Subscription Required

Therapy

Subscription Required

References

Subscription Required

Last Reviewed: 06/19/2018
Last Updated: 05/03/2019
Copyright © 2019 VisualDx®. All rights reserved.
Metachromatic leukodystrophy
Print 1 Images
Metachromatic leukodystrophy : Ataxia, Gait disturbance, Nystagmus, Optic disc atrophy, Spasticity, Memory loss
Copyright © 2019 VisualDx®. All rights reserved.